PRESS RELEASES

To receive all future Arrow press releases please click here.

To view AstraZeneca press releases please click here.

Ken Powell To Leave Arrow Therapeutics

Antiviral company Arrow Therapeutics, a fully-owned subsidiary of AstraZeneca (AZ), announced today that Ken Powell will step down as Head of Arrow.  The company was founded by Dr. Powell and colleagues in 1998, re-located to London from Carshalton, Sutton in 2001 and acquired by AZ in February 2007.  Arrow's main programmes focus on hepatitis C (HCV) and respiratory syncytial virus (RSV) with 3 clinical leads. 

After two years of helping the transition of the small molecule company into a successful antiviral drug discovery and development entity of AZ, Dr. Powell felt the time was right to step down and pursue other interests.  Dr. Stuart Cockerill, Research Director, will take over in the interim as Head of Arrow.  Stuart joined Arrow from GlaxoSmithKline where he was one of the senior Group Leaders in Medicinal Chemistry.

Ken has extensive experience in the pharmaceutical industry and academia; his previous posts have included Head of Antiviral Research and Head of Biology at the Wellcome Foundation. He was Professor of Virology and Cell Biology at the Wolfson Institute for Biomedical Research (UCL) and during his time at WIBR, Ken set up Inpharmatica (now part of Galapagos NV) and Ark Therapeutics (now LSE listed).  He is currently Executive Chairman of Q-Chip a Cardiff based biotechnology company.

LATEST NEWS

Press Release Archive